Net-clinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more
Academic Article
Publication Date:
2019
abstract:
Extended-duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin. We aimed to assess the risk-benefit of betrixaban in patients aged ≥ 80 years enrolled in the APEX trial.
Iris type:
Articolo su Rivista
Keywords:
betrixaban; elderly; medical patients; prophylaxis; venous thromboembolism; Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Benzamides; Blood Coagulation; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Progression-Free Survival; Pyridines; Risk Assessment; Risk Factors; Time Factors; Venous Thromboembolism
List of contributors:
Ageno, Walter; Lopes, Renato D; Yee, Megan K; Hernandez, Adrian; Hull, Russell D; Goldhaber, Samuel Z; Gibson, C Michael; Cohen, Alexander T
Published in: